Biomedical Applications: Advances in Bioengineering and Drug Delivery, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 1314

Special Issue Editors


E-Mail Website
Guest Editor
Escuela de Química y Farmacia, Facultad de Medicina, Universidad Andrés Bello, Santiago 8320000, Chile
Interests: intracellular nanoparticle trafficking; biological properties of natural and synthetic compounds; immunomodulation by biomaterials
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Departamento de Química y Medio Ambiente, Universidad Técnica Federico Santa María, Valparaíso 2390123, Chile
Interests: nanoformulations; nerve tissue engineering; biomaterials; organ on a chip
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, significant strides have been made in the development of bioengineering and in intelligent drug delivery systems. In the area of bioengineering, there are outstanding advances in biological therapy with proteins and antibodies, the development of new materials for tissue engineering, and the generation of biosensing systems. In parallel, as well as from advances in bioengineering, drug delivery and delivery systems have been successfully researched and developed with the idea of improving efficiency and thus reducing adverse drug effects.

These areas of development include various scientific aspects that must be addressed for the understanding of the processes involved and the development of efficient systems. In this context, the study of physical and chemical interactions between the components of biological systems, the relationships between biochemical mechanisms and the physiological implications of the processes studied have a significant impact on the success of new proposals.

This Special Issue brings together the new results of research related to the different aspects of bioengineering development focused on investigation of therapeutic alternatives, in addition to allowing the incorporation of reviews and short communications that offer readers a broad vision of the capabilities of these developing technologies.

Dr. María Carolina Otero
Prof. Dr. Yusser Olguín
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomedicine
  • tissue engineering
  • biomaterials
  • drug carrier
  • biological therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

31 pages, 2438 KB  
Review
Integrative Peptide Drug Development: Chemical Engineering, AI-Driven Design, and Cell-Penetrating Peptides
by Yong Eun Jang, Minjun Kwon, Chan Woo Kwon, Seok Gi Kim, Ji Su Hwang, Nimisha Pradeep George, Seung Ryong Paik, Sampa Misra, Shaherin Basith, Seung Soo Sheen and Gwang Lee
Pharmaceutics 2026, 18(5), 537; https://doi.org/10.3390/pharmaceutics18050537 - 28 Apr 2026
Viewed by 977
Abstract
Peptide therapeutics occupy a unique chemical space between small molecules and biologics, combining high target specificity with structural programmability and favorable safety profiles. Recent regulatory approvals and expanding clinical pipelines underscore the growing therapeutic and commercial relevance of peptide-based drugs. This review outlines [...] Read more.
Peptide therapeutics occupy a unique chemical space between small molecules and biologics, combining high target specificity with structural programmability and favorable safety profiles. Recent regulatory approvals and expanding clinical pipelines underscore the growing therapeutic and commercial relevance of peptide-based drugs. This review outlines chemical modification approaches and contemporary design strategies, and evaluates their impact on proteolytic stability, pharmacokinetics, membrane permeability, and target engagement. We then highlight recent advances in artificial intelligence (AI)-guided peptide drug design, including machine learning models, protein language models, and generative architectures that enable high-throughput activity prediction, property optimization, and de novo sequence generation. These approaches collectively accelerate the traditional discovery–design–validation cycle while reducing experimental attrition through data-driven, structure-informed modeling frameworks. Among these applications, AI also enables the rational design of cell-penetrating peptides (CPPs) to enhance intracellular delivery and biological activity. Building on these methodological advances, we further examine their application to peptide therapeutics, with particular emphasis on AI-based predictive models for CPPs as well as on therapeutic applications within the central nervous and pulmonary systems. We conclude by outlining future perspectives and emphasize that the systematic integration of AI-enabled sequence design with rational chemical engineering and advanced delivery technologies, supported by rigorous experimental validation, will be critical for developing robust and clinically durable peptide-based medicines. Full article
Show Figures

Figure 1

Back to TopTop